Pazopanib HCI

Pazopanib is a multi-receptor tyrosine kinase inhibitor. It inhibits multi-target tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFR) -1, -2, and -3, platelet-derived growth factor

IUPAC name:

5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide;hydrochloride

CAS No.

635702-64-6

Molecular Weight:

474.0 g.mol−1

Molecular Formula:

C21H24ClN7O2S

Granule:

Available - Ready to press

Mechanism Of Action:

Pazopanib is a second-generation multi-targeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor-1, -2, and -3, platelet-derived growth factor receptor-alpha, platelet-derived growth factor receptor-beta, and c-kit. These receptor targets are part of the angiogenesis pathway that facilitates the formation of tumor blood vessel for tumor survival and growth.

Indication:

First-line treatment of advanced renal cell carcinoma,
Treatment of advanced renal cell carcinoma in patients who have had previous treatment with cytokine therapy.
Treatment of adult patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy.

information

Category: Oncology

January 21, 2024

Desloratadine

Anti-Histamine

Cas No: 100643-71-8

Mechanism Of Action: Desloratadine is a non-sedating, long-acting antihistamine that selectively blocks peripheral histamine H1-receptors. It is the major active metabolite of loratadine and works

Voriconazole

Anti-Microbial

Cas No: 137234-62-9

Mechanism Of Action: Voriconazole is a triazole antifungal agent that works by inhibiting the fungal cytochrome P450 enzyme 14-alpha-lanosterol demethylase1. This enzyme is crucial for

Enoxaparin Sodium

Cardiovascular

Cas No: 679809-58-6

Mechanism Of Action: Enoxaparin, a low molecular weight heparin (LMWH), works primarily by activating antithrombin III, which in turn inhibits factor Xa and IIa (thrombin).

Tirzapatide

Anti-Diabetic

Cas No: 2023788-19-2

Mechanism Of Action : Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This means it mimics the

Lenvatinib Mesylate

Oncology

Cas No: 857890-39-2

Mechanism Of Action: Lenvatinib is classified as a receptor tyrosine kinase (RTK) inhibitor that effectively suppresses the kinase activities of vascular endothelial growth factor (VEGF)

TRAMETINIB DIMETHYL SULFOXIDE

Oncology

Cas No: 1187431-43-1

Mechanism Of Action: Trametinib is identified as a reversible and remarkably selective allosteric inhibitor of MEK1 and MEK2. Through its high-affinity binding to unphosphorylated MEK1